In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

This content is currently on FREE ACCESS, enjoy another 101 days of free consultation


The cardioprotective effect of FFR-significant multivessel disease detected by cardiac magnetic resonance imaging in patients following ST-segment elevation myocardial infarction. Results from DANAMI3

Session Innovations in CMR for coronary artery disease

Speaker Kathrine Ekstroem

Congress : ESC Congress 2019

  • Topic : imaging
  • Sub-topic : Cardiac Magnetic Resonance: Myocardium
  • Session type : Moderated Posters
  • FP Number : P3096

Authors : K Ekstroem (Copenhagen,DK), JVW Nielsen (Copenhagen,DK), L Nepper-Christensen (Copenhagen,DK), KA Ahtarovski (Copenhagen,DK), K Kyhl (Copenhagen,DK), C Goeransson (Copenhagen,DK), L Bertelsen (Copenhagen,DK), AA Ghotbi (Copenhagen,DK), H Kelbaek (Roskilde,DK), DE Hoefsten (Copenhagen,DK), L Koeber (Copenhagen,DK), MM Schoos (Copenhagen,DK), N Vejlstrup (Copenhagen,DK), J Loenborg (Copenhagen,DK), T Engstroem (Copenhagen,DK)

K Ekstroem1 , JVW Nielsen1 , L Nepper-Christensen1 , KA Ahtarovski1 , K Kyhl1 , C Goeransson1 , L Bertelsen1 , AA Ghotbi1 , H Kelbaek2 , DE Hoefsten1 , L Koeber1 , MM Schoos1 , N Vejlstrup1 , J Loenborg1 , T Engstroem1 , 1Rigshospitalet - Copenhagen University Hospital, Department of Cardiology - Copenhagen - Denmark , 2University Hospital, Department of Cardiology - Roskilde - Denmark ,


Background In patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI), reperfusion injury accounts for a significant part of the final infarct size, which is directly related to patient prognosis. In animal studies brief periods of ischemia in non-infarct related coronary arteries protects the myocardium via remote ischemic perconditioning. Fractional flow reserve (FFR) measures functional significant coronary stenosis which may offer remote ischemic perconditioning of the myocardium. It has not previously been investigated if FFR-significant stenosis in non-culprit myocardium offers cardioprotection following STEMI. 

Purpose To investigate cardioprotective effect of FFR-significant multivessel disease (MVD) on final infarct size and myocardial salvage in a large contemporary cohort of patients with ST-segment elevation myocardial infarction (STEMI).

Methods and results We included 509 patients with STEMI from the DANAMI-3 trial, divided into three groups: 388 (76%) patients had single vessel disease (SVD), 34 (7%) had non-FFR-significant MVD and 192 (17%) had FFR-significant MVD. CMR was performed at baseline and three months after primary PCI. There was no difference in final infarct size; mean infarct size (% left ventricular mass) SVD 9±3%; non-FFR-significant MVD 9±3%; and FFR-significant MVD 9±3%, p=0.95, or in myocardial salvage index (MSI) between groups, calculated as (area-at-risk – infarct size)/area-at-risk; mean index (%) SVD 67±23%; non-FFR-significant MVD 68±19%; and FFR-significant MVD 67±21%, p=0,99. In multivariable regression analyses FFR-significant MVD was not associated med larger MSI (p=0.84) or lower infarct size (p=0.60).

Conclusions FFR-significant functional MVD of non-culprit myocardium does not offer cardioprotection in patients following STEMI. 

Figure 1
A: Late gadolinium (LGE) cardiac magnetic resonance (CMR) image of a mid-ventricular short-axis slice. Hyperintense signals (arrow) shows contrast enhancement in the anterior-septal segments, indicating myocardial infarction (MI).

B: Same patient. T2-weighted image of the same mid-ventricular short-axis slice. Hyperintense signals (arrows) shows edema in the anterior-septal segments.

This content is currently on FREE ACCESS, enjoy another 101 days of free consultation


Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are